4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2025)
Historic Cash from Investing Activities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $17.8 million.
- 4D Molecular Therapeutics' Cash from Investing Activities fell 3488.15% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year increase of 11357.87%. This contributed to the annual value of -$302.4 million for FY2024, which is 36135.92% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Cash from Investing Activities stood at $17.8 million, which was down 3488.15% from -$13.9 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Cash from Investing Activities registered a high of $57.5 million during Q2 2022, and its lowest value of -$263.3 million during Q1 2024.
- Its 5-year average for Cash from Investing Activities is -$17.9 million, with a median of -$642000.0 in 2021.
- Per our database at Business Quant, 4D Molecular Therapeutics' Cash from Investing Activities plummeted by 3993094.56% in 2021 and then soared by 789755.77% in 2022.
- 4D Molecular Therapeutics' Cash from Investing Activities (Quarter) stood at -$32.3 million in 2021, then dropped by 10.8% to -$35.8 million in 2022, then surged by 81.32% to -$6.7 million in 2023, then soared by 205.64% to $7.1 million in 2024, then soared by 151.85% to $17.8 million in 2025.
- Its Cash from Investing Activities stands at $17.8 million for Q3 2025, versus -$13.9 million for Q2 2025 and $31.9 million for Q1 2025.